These two stocks could have vastly different long-term performances.It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF, is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain.Of course, it's not hard to find stocks that have performed both better and worse than the sector average. Consider CRISPR Therapeutics (CRSP 0.96%), a mid-cap biotech that is down by 13% this year. On the other end of the spectrum is Ocugen (OCGN ...